Amarin to Present at Oppenheimer & Co. Inc. Annual Healthcare Conference

DUBLIN and MYSTIC, Conn., Oct. 28 /PRNewswire-FirstCall/ — Amarin Corporation plc (Nasdaq: AMRN) today announced that Dr. Declan Doogan, Chief Medical Officer, is scheduled to present on Amarin’s behalf at the Oppenheimer & Co. Inc. 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:10 pm. This conference will be held at the Waldorf Astoria in New York City. Colin Stewart, Amarin’s President and Chief Executive Officer, will also be at the conference representing Amarin in meetings with investors.

A live audio webcast of the presentation will be available at the following URL:

http://www.veracast.com/webcasts/opco/healthcare2010/06210589.cfm

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia on statin therapy. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.

    Contacts:
    Investor Contact Information:
    John F. Thero
    Chief Financial Officer
    In US: +1 (860) 572 4979
    investor.relations@amarincorp.com

    Lee M. Stern
    The Trout Group
    In U.S. +1 (646) 378-2922
    lstern@troutgroup.com

    International Media Contact Information:
    Mark Swallow or David Dible
    Citigate Dewe Rogerson
    In UK: +44 (0)207 638 9571
    mark.swallow@citigatedr.co.uk

SOURCE Amarin Corporation plc